Cargando…
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance. Cont...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636498/ https://www.ncbi.nlm.nih.gov/pubmed/34853302 http://dx.doi.org/10.1038/s41467-021-26572-6 |